Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

What is the most important approach in current drug discovery: doing the right things or doing things right?

Elebring T, Gill A, Plowright AT.

Drug Discov Today. 2012 Nov;17(21-22):1166-9. doi: 10.1016/j.drudis.2012.04.009. Epub 2012 Apr 27.

PMID:
22569181
2.

Different in vitro and in vivo profiles of substituted 3-aminopropylphosphinate and 3-aminopropyl(methyl)phosphinate GABA(B) receptor agonists as inhibitors of transient lower oesophageal sphincter relaxation.

Lehmann A, Antonsson M, Aurell-Holmberg A, Blackshaw LA, Brändén L, Elebring T, Jensen J, Kärrberg L, Mattsson JP, Nilsson K, Oja SS, Saransaari P, von Unge S.

Br J Pharmacol. 2012 Mar;165(6):1757-1772. doi: 10.1111/j.1476-5381.2011.01682.x.

3.

Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules.

Luker T, Alcaraz L, Chohan KK, Blomberg N, Brown DS, Butlin RJ, Elebring T, Griffin AM, Guile S, St-Gallay S, Swahn BM, Swallow S, Waring MJ, Wenlock MC, Leeson PD.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5673-9. doi: 10.1016/j.bmcl.2011.07.074. Epub 2011 Jul 27.

PMID:
21852131
4.

(R)-(3-amino-2-fluoropropyl) phosphinic acid (AZD3355), a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action.

Lehmann A, Antonsson M, Holmberg AA, Blackshaw LA, Brändén L, Bräuner-Osborne H, Christiansen B, Dent J, Elebring T, Jacobson BM, Jensen J, Mattsson JP, Nilsson K, Oja SS, Page AJ, Saransaari P, von Unge S.

J Pharmacol Exp Ther. 2009 Nov;331(2):504-12. doi: 10.1124/jpet.109.153593. Epub 2009 Jul 31.

PMID:
19648470
5.

Making medicinal chemistry more effective--application of Lean Sigma to improve processes, speed and quality.

Andersson S, Armstrong A, Björe A, Bowker S, Chapman S, Davies R, Donald C, Egner B, Elebring T, Holmqvist S, Inghardt T, Johannesson P, Johansson M, Johnstone C, Kemmitt P, Kihlberg J, Korsgren P, Lemurell M, Moore J, Pettersson JA, Pointon H, Pontén F, Schofield P, Selmi N, Whittamore P.

Drug Discov Today. 2009 Jun;14(11-12):598-604. doi: 10.1016/j.drudis.2009.03.005. Epub 2009 Mar 11. Review.

PMID:
19508922
6.

Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors.

Alstermark C, Amin K, Dinn SR, Elebring T, Fjellström O, Fitzpatrick K, Geiss WB, Gottfries J, Guzzo PR, Harding JP, Holmén A, Kothare M, Lehmann A, Mattsson JP, Nilsson K, Sundén G, Swanson M, von Unge S, Woo AM, Wyle MJ, Zheng X.

J Med Chem. 2008 Jul 24;51(14):4315-20. doi: 10.1021/jm701425k. Epub 2008 Jun 25.

PMID:
18578471
7.

The orphan receptor GPR55 is a novel cannabinoid receptor.

Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ.

Br J Pharmacol. 2007 Dec;152(7):1092-101. Epub 2007 Sep 17.

8.

Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists.

Boström J, Berggren K, Elebring T, Greasley PJ, Wilstermann M.

Bioorg Med Chem. 2007 Jun 15;15(12):4077-84. Epub 2007 Mar 30.

PMID:
17433696
9.

Effects of (2R)-(3-amino-2-fluoropropyl)sulphinic acid (AFPSiA) on transient lower oesophageal sphincter relaxation in dogs and mechanism of hypothermic effects in mice.

Lehmann A, Holmberg AA, Bhatt U, Bremner-Danielsen M, Brändén L, Elg S, Elebring T, Fitzpatrick K, Geiss WB, Guzzo P, Jensen J, Jerndal G, Mattsson JP, Nilsson K, Olsson BM.

Br J Pharmacol. 2005 Sep;146(1):89-97.

10.

Identification and characterisation of a novel splice variant of the human CB1 receptor.

Ryberg E, Vu HK, Larsson N, Groblewski T, Hjorth S, Elebring T, Sjögren S, Greasley PJ.

FEBS Lett. 2005 Jan 3;579(1):259-64.

11.

Novel structures derived from 2-[[(2-pyridyl)methyl]thio]-1H-benzimidazole as anti-Helicobacter pylori agents, Part 1.

Kühler TC, Swanson M, Christenson B, Klintenberg AC, Lamm B, Fägerhag J, Gatti R, Olwegård-Halvarsson M, Shcherbuchin V, Elebring T, Sjöström JE.

J Med Chem. 2002 Sep 12;45(19):4282-99.

PMID:
12213070
12.

6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.

Stjernlöf P, Elebring T, Nilsson J, Andersson B, Lagerkvist S, Svensson K, Ekman A, Carlsson A, Wikström H.

J Med Chem. 1994 Sep 30;37(20):3263-73.

PMID:
7932553
13.

(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists.

Stjernlöf P, Gullme M, Elebring T, Andersson B, Wikström H, Lagerquist S, Svensson K, Ekman A, Carlsson A, Sundell S.

J Med Chem. 1993 Jul 23;36(15):2059-65.

PMID:
8340910
14.

6-Hydroxy-3-n-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine and analogs: new centrally acting 5-HT1A receptor agonists.

Wikström H, Andersson B, Elebring T, Lagerkvist S, Hallnemo G, Pettersson I, Jovall PA, Svensson K, Ekman A, Carlsson A.

J Med Chem. 1992 Oct 30;35(22):3984-90.

PMID:
1433207
16.

Occurrence and pharmacological significance of metabolic ortho-hydroxylation of 5- and 8-hydroxy-2-(di-n-propylamino)tetralin.

Wikström H, Elebring T, Hallnemo G, Andersson B, Svensson K, Carlsson A, Rollema H.

J Med Chem. 1988 Jun;31(6):1080-4.

PMID:
2967374
17.

N-substituted 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines and 3-phenylpiperidines: effects on central dopamine and sigma receptors.

Wikström H, Andersson B, Elebring T, Svensson K, Carlsson A, Largent B.

J Med Chem. 1987 Dec;30(12):2169-74.

PMID:
2824773
18.

Resolved cis-10-hydroxy-4-n-propyl-1,2,3,4,4a,5,6,10b- octahydrobenzo[f]quinoline : central serotonin stimulating properties.

Wikström H, Andersson B, Elebring T, Jacyno J, Allinger NL, Svensson K, Carlsson A, Sundell S.

J Med Chem. 1987 Sep;30(9):1567-73.

PMID:
3625704

Supplemental Content

Loading ...
Support Center